Physician profile
Jennifer Mathews
NPI 1134105406
$9,768.72
in general payments reported to CMS, 2019-2025
46 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $1,123 · 2021: $1,408 · 2022: $1,438 · 2023: $1,472 · 2024: $1,260 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,639.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.27 | 2019-2025 | |
| Novo Nordisk INC | $1,020.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $846.18 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $766.48 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $656.21 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $645.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $462.43 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $454.09 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.17 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $357.30 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $308.67 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $278.62 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.76 | 2019-2025 | Trintellix |
| Lundbeck LLC | $221.89 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $219.21 | 2021-2025 | Keveyis, Gvoke Hypopen |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $208.58 | 2022-2025 | Austedo Xr, Austedo Xr |
| Sanofi-Aventis U.S. LLC | $193.85 | 2019-2023 | |
| Astellas Pharma US INC | $186.80 | 2019-2025 | Veozah |
| Dexcom, INC. | $139.87 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.44 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Abbott Laboratories | $100.92 | 2019-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $83.72 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $82.03 | 2020-2023 | Yupelri |
| Inari Medical, INC. | $77.49 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kowa Pharmaceuticals America, INC. | $74.30 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $52.03 | 2020-2021 | |
| Esperion Therapeutics, INC. | $50.29 | 2020-2021 | |
| Axsome Therapeutics, INC. | $49.47 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $43.80 | 2020-2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $41.99 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $40.93 | 2021 | |
| Allergan, INC. | $40.36 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $32.51 | 2023-2024 | Eliquis |
| Eisai INC. | $30.99 | 2020-2021 | |
| Radius Health, INC. | $29.66 | 2024 | Tymlos |
| Gilead Sciences, INC. | $29.23 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.30 | 2022 | |
| Argenx US, INC. | $27.13 | 2025 | Vyvgart Hytrulo |
| Tactile Systems Technology INC | $22.40 | 2024 | Entre Plus, Flexitouch Plus |
| Strongbridge US INC. | $18.85 | 2020 | |
| Daiichi Sankyo INC. | $18.53 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.56 | 2025 | Caplyta |
| Corcept Therapeutics | $14.97 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $14.80 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $12.98 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.